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Interstitial pneumonitis after rituximab theraphy for non 
hodgikin’s lymphoma: the radiological findings
Kim, Ji Yeon; Do, Kyung-Hyun; Lee, Jin Seong 
Research Institute of Radiology, Department of Radiology, Asan Medi-
cal Center, University of Ulsan College of Medicine, Seoul, Korea
Background: Rituximab, anti-CD20 IgG1 monoclonal antibody, is an 
important chemotherapeutic agent for non Hodgikin lymphoma. This 
drug is generally tolerated, but it can be associated with various adverse 
effects, including coughing, rhinitis, bronchospasm or dyspnea. Also 
this drug has rarely been late pulmonary complication, such as intersti-
tial pneumonia and fatal alveolar hemorrhage. 
CT ﬁndings of the rituximab induced interstitial lung disease have not 
been documented to our knowledge. We suggested the radiological 
ﬁnding of the rituximab induced interstitial lung disease on chest CT 
and positron emission tomography.
Materials and Methods: We reviewed nineteen patients, who had 
received rituximab for non-Hodgikin B cell lymphoma and complained 
respiratory symptoms after treated with rituximab, between March 
2003 and November 2004. Finally three patients (one men and two 
women; age range, 46-67 years; mean age, 58 years) noticed episodic 
symptom of dry cough, dyspnea or DOE after each rituximab infusion 
for no particular reason. They performed chest CT using 16 channel 
multi-detector CT and positron emission tomography using F-18 ﬂuo-
rodeoxyglucose. As two patients underwent bronchoscopic biopsy, one 
patient was showed with diffuse alveolar damage and focal bronchiol-
itis obliterance with organizing pneumonia component and the other 
patient was showed chronic interstitial inﬂammation.
Results: CT scan revealed patchy ground glass opacities and interlobu-
lar septal thickening throughout the bilateral lung parenchyma with 
posterior predominancy. 
In two patients, proton emission tomograph demonstrated diffuse hy-
permetabolic lesions with predominantly dependent portion (max SUV 
1.0 - 2.2) in the bilateral lung parenchyma, correlated with CT ﬁnding. 
There was no hypermetabolic lesion in the one patient, and his CT ﬁnd-
ings were subtlest in the three patients.
Previous two patients were followed chest CT scan with steroid ther-
apy, diffuse ground glass opacities were disappeared. Dyspnea of the 
other patient with subtlest CT ﬁndings was improved after rituximab 
was stopped.
Conclusion: In any patients with a history of rituximab therapy who 
complain new or progressive respiratory symptoms, if the diffuse 
ground glass attenuation was noted on HRCT and diffuse mild hyper-
metabolic lesions in the bilateral lung parenchyma on PET, pulmonary 
toxicity of the rituximab theraphy should be considered.
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The influence of positron emission tomography (FDG-PET/CT) on 
management of patients with non small cell lung cancer (NSCLC)
Kim, Su Woon1 Appel, Wiebke1 Hill, Jonathan1 Coffey, John1 Kane, 
Thomas2 
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Aims: To assess the inﬂuence of PET/CT scan compared to Com-
puted Tomography (CT) in management of non small cell lung cancer 
(NSCLC). 
Background: Access to PET/CT scanning has been very variable in 
the United Kingdom. Following guidance by the National Institute of 
Clinical Excellence (NICE) in Feb 2005 there was some interest from 
the local Primary Care Trusts (PCT) to investigate whether investment 
into a PET/CT scanner was valuable to patients in the cancer network.
Patients and methods: 107 patients at one cancer centre underwent 
PET/CT scanning for suspected lung cancer between September 2005 
and March 2006. PET/CT results were compared with the ﬁndings of 
CT scans on the same patients. Subsequent assessment revealed benign 
pathology in 37 patients and NSCLC in 70 patients. A retrospective 
analysis of these 70 patients was performed. The following questions 
were asked: demographic details, histology, TNM stage (both CT and 
PET/CT), Date of scans, management decision based on CT and PET/
CT, any changes in management decision.
Results: When comparing CT scan stage with stage of PET/CT scan, 
30/70 cases (43%) were upstaged and 11 cases (16%) were downstaged 
